Advanced Enzyme Technologies Ltd

The earnings conference call for Advanced Enzyme Technologies Limited on August 12, 2026, discussed the company's unaudited financial results for Q1 FY27. Management reported a top line of INR 1,898 million, reflecting a 2% year-over-year growth but a 7% decline sequentially. EBITDA was INR 510 million, down 10% YoY and 19% QoQ, with a margin of 27%. Profit after tax was INR 386 million, a decrease of 5% YoY and 15% sequentially. The Human Healthcare segment saw a 7% YoY decline, while Bioprocessing and Specialized Manufacturing segments reported growths of 30% and 41% YoY, respectively. Management announced a buyback of INR 697 million and the acquisition of a 4.28% stake in JC Biotech, making it a wholly-owned subsidiary. The call emphasized the need to evaluate performance on an annual basis due to market volatility and geopolitical challenges.

Management highlighted both growth opportunities and challenges faced in the current operating environment.